Global med-tech company Siemens Healthineers on Tuesday said it plans to invest Rs 1,300 crore over the next five years in an innovation hub in Bengaluru.
The investment aims to make India a manufacturing centre for the company's emerging market products.
The innovation hub will be housed in a new campus that will combine R&D and manufacturing to make India a centre of competence for the design and development of entry-level products, said the company headquartered in Erlangen, Germany.
Siemens Healthineers said it plans to hire an additional 1,800 skilled digital tech experts to expand its digital capabilities in the next 10 years.
"This investment is the largest we have ever made in India. It will play a key role in taking our business to the next level by driving digitalisation and expanding our portfolio for emerging markets," Elisabeth Staudinger, President Asia Pacific, Siemens Healthineers, said in a statement.
"The innovation hub in Bengaluru will demonstrate our commitment to advance healthcare through cutting edge digital technologies as well as through accessible and affordable innovations driven from India."
When completed in 2025, the first phase of the new campus will include 70,000 square meters of office space for the enlarged R&D centre and 5,000 square metres of factory space, the company said.
The Bengaluru campus will be one of four innovation hubs of the company, with the other hubs located in the US, Germany, and China.
The innovation hub at Bengaluru will include centres of competence in digital technologies such as data analytics, Artificial Intelligence (AI), immersive technologies like augmented and virtual reality, user experience, and cybersecurity.
Siemens Healthineers said it has already invested about Rs 2,500 crore in R&D in India.
With about 50 per cent of all the software engineers in Siemens Healthineers, the existing R&D centre at Bengaluru plays a strategic role in developing cutting edge software products and platforms for all three segments of the company -- imaging, diagnostics, and advanced therapies.
--IANS
gb/bg
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)